CCCC
C4 Therapeutics Inc
NASDAQ: CCCC · HEALTHCARE · BIOTECHNOLOGY
$3.52
-0.85% today
Updated 2026-07-29
Market cap
$403.57M
P/E ratio
—
P/S ratio
11.58x
EPS (TTM)
$-1.10
Dividend yield
—
52W range
$2 – $5
Volume
3.2M
C4 Therapeutics Inc (CCCC) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$3.52
12-Month target
—
2030 Target
—
Intrinsic (DCF)
$6.65
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.0B | $0.0B | $0.0B | $0.0B | $0.0B | $0.0B | $0.0B | $0.0B | $0.0B |
| EPS | — | — | — | — | — | — | — | — | — |
CAGR applied: 1.61% (capped 20%) · P/E: 25.00x (capped 25x) · Margin: -297.80%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.